Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215 28 September 2021 | Press release
More exciting press coverage following $153 Million financing – Series C 27 August 2021 | Media coverage
Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X 27 July 2021 | Press release
Exciting press coverage following our Polθ (Pol-theta) press release – Nature Communications 1 July 2021 | Media coverage
Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications 17 June 2021 | Press release
Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies 7 April 2021 | Press release
Artios Pharma to Attend Upcoming Conferences in February and March 2021 18 February 2021 | Press release
Niall Martin, Chief Executive Officer presented a company overview at LifeSci Partners Precision Oncology Day 17 February 2021 | Conferences